Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The Material information is topline data readout and they have had it for months...probably by January. IMO, sitting on it for a Journal article may give you some leeway, but holding it because you are afraid someone may try to poke holes in it is not a valid reason to delay.
If they said, in April last year, we should get to data lock this fall and start the process to unblinding, which could take another year...we would be in pennyland, no doubt. BUT, after stating we would have topline by this time LAST year, and staying silent in a so-called "quiet-period" since then? Ridiculous. There is nothing negative that would happen if they simply told us where they are in the process. Just tell us what boxes have been checked. The notion that they would piss off the FDA if they gave an update, nonsense. They have a fiduciary responsibility to shareholders and they are 100% sitting on material information...for months at a minimum.
It will be over $1.60 by then. fewer shares i guess.
I think it is a flash crash for this morning. Wouldn't be surprised to see a move back up this afternoon. Things are really squeezing, IMO. There has to be news over the next week or so. Too much hanging out there. If no news by October 5th...then we could see $1 or lower, IMO.
Not going to get there. $1.40 is new support for now. This is just a pullback from new breakthrough high. Likely treads water until this afternoon and we get back through $1.47.
I'm sure it's in the works but uplist will be a ways off, IMO. Other fish to fry....TOPLINE, for one.
Low volume takedown, holding PPS under $1.47...battle today.
We will still be limited to individual retail investors until we are over $5/share, on any exchange. We need positive data and Journal. The rest takes care of itself.
If the ask stays where it is, we should break the elusive $1.47 this morning on the open. If if holds, we run today. If not, could be a test, fallback and retest for break through. We are a week away from 1yr post data lock, waiting on Sawston Certification, third quarter ends....something has to give!!!!
$1.47 is the resistance we need to get through. If that happens, clear to $1.60.
If the short-timers take their weekly profits, we are going to be at $1.37. If they hold and let this run we could see $1.59.
That's a big jump in one day. Clearly they didn't sell most of them. Good Sign.
Ok, we held up into the close. Let's see if we get a FOMO Friday or a sell off friday.
Warrant conversion cash. Millions of new shares have been issued this year due to warrants. Not all are cash, but it seems enough are.
It looks very calculated right now. Extremely narrow one-cent ranges. Building pressure. When the MM's step aside, this should pop. A strong close at $1.45 today and I agree we could have a good Friday.
I think they will PR it. I just don't think the certification will have as much impact on PPS as some here do. I hope I am wrong. Until there is positive, validated topline data, there is limited impact that the certification will have. Specials treatments and potential income are unknown, especially without positive data. We know what they CAN treat as far as volume, but not what they WILL get as far as patients and the price tag prior to approval without healthcare payment approval.
And from the longer view you show, that is almost a one year bull pennant and the breakouts are usually stronger from a set up like that.
True. We also have some space above $1.47 so if we get through that with decent volume, the run to $1.60 could be quick. That is what I am expecting.
They will move out of the way after lunch and let this run, that's my guess.
It invalidates the short squeeze thesis for those who believe the short shares are legal. There are some, LP included, who believe there are hundreds of millions of naked short shares. I would be there are some, but not in those numbers.
My opinion. Technically oversold. Buy the rumor (patent, Sawston approval, upcoming conferences, 1yr data lock). Maybe, just maybe, we actually get topline and Journal "in the coming months"....we have to be getting close.
agreed.
It is good to finally see some volume increasing every day. We need to see 5-10M shares a day to move the stock, like the last larger moves. 2M by lunchtime has been rare these days. Hoping to see afternoon conviction of this move.
I was hoping the patent info was updated with recent trial tables and results but we do not know when it was updated, do we? Meaning, when (or was) additional, more recent data added into the patent application?
I believe they are having discussions with friendly warrant holders and asking for conversion to float the boat. Not disclosing anything, just asking for believers to convert so there is cash coming in.
Great Patent approval, VERY material, IMO. Should see a PR today. Interesting they use survival graphs! Wonder when it was last updated? "DC's are the treatment of choice for immunotherapy!" However, many have not used them as they do not know the secret sauce. Specific maturation process to get full effectiveness. This, to me, is not just a GBM patent, this is the one that could apply to all solid tumors.
Not without news. No Way.
I think the PPS would have continued higher today without the China property debt worries. Hopefully tomorrow things settle down and we move higher. Or, this 800 point slide is the beginning of the correction that takes us back under 30k....
LP thinks the Journal article (And saying the same process over and over again since last Oct 5th) will protect her from sitting on material information and not disclosing it.
Can't have a publication without topline data so I would say topline is all that matters. Journal to follow right after. Question is how long you can hold topline results while waiting on a journal review. They are clearly sitting on material information.
We are two weeks away from being 1yr post data lock. 350 days. Advent is not an NWBO-owned company. Manufacturing approval there is great but has anyone seen any revenue structure? Not even sure what we pay them and what our net will be so I'm not as excited as some here are about this approval. Third quarter ends in 10 days, 55 days until 10Q. An eternity. We need to hear from NWBO on where we are in the topline data release process.
That's fine. That's not what I am talking about. Friday afternoon PR's from companies (and politicians) are usually bad news.
Would love to see it after these last weeks of nothingness. Do not want news on a Friday though. Terrible news usually gets dropped on Fridays.
Lol, no apologies needed. Like this chart better!
Agreed.
All that is true. All I'm saying is that this new conference session is not the big reveal. I don't think it will be at a conference. We are still at the mercy of Journal review and timing, which is the big question mark for timing.
It's not just LL's show, the other guy is:
E. Antonio Chiocca, MD, PhD
Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School
Neurosurgeon-in-Chief and Chairman, Department of Neurosurgery, Brigham and Women's Hospital
Biology & Treatment of Malignant Brain Tumors
Glioblastomas (GBM) are one of the deadliest forms of cancer. Understanding the biology of these tumors is critical for developing new therapeutic strategies.
The Chiocca lab is deeply interested both in the biological basis of brain cancer and in designing experimental therapeutics. We have been focused on developing novel genetic therapies, with one major approach being the engineering of viruses that can kill tumor cells without affecting normal brain cells. We are currently combining this research with novel pharmacological and immunotherapeutic approaches for brain cancer.
One major project is the preclinical evaluation of oncolytic viruses for glioma therapy. This project focuses on the development of a recombinant Herpes virus that specifically kills brain cancer cells and is currently in phase I clinical trial. As part of this work, we study how to improve immune responses against GBM.